Generic Name and Formulations:
Epoprostenol (as sodium) 0.5mg, 1.5mg; per vial; pwd for IV infusion after reconstitution.
Indications for FLOLAN:
Primary pulmonary hypertension. Pulmonary hypertension due to scleroderma disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Give by continuous chronic IV infusion through a central venous catheter. Initially 2 nanograms/kg per min; increase in increments of 2 nanograms/kg per min at ≥15 minute intervals until response achieved or tolerance develops. Dose decreases should be made gradually in 2 nanograms/kg/min decrements at ≥15 minute intervals until dose-limiting effects resolve.
Chronic use with CHF due to severe left ventricular systolic dysfunction. Pulmonary edema.
Avoid abrupt withdrawal or large dose reductions (may cause rebound pulmonary hypertension). Bleeding disorders. Start anticoagulant therapy, unless contraindicated. Monitor BP and heart rate for several hours after dose changes. Pregnancy (Cat.B). Labor & delivery. Nursing mothers.
Potentiated hypotensive effects with diuretics, antihypertensive agents, other vasodilators. Potentiates anticoagulants, antiplatelet agents. May potentiate digoxin (monitor).
Headache, jaw pain, flushing, GI upset, flu-like symptoms, anxiety, dizziness, tachycardia, myalgia.
Vials—1 (w. diluent)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|